1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,840 | 3,970 | 08.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | MaaT Pharma: €37.5 Million EIB Loan Secured To Advance Cancer Therapies | 3 | pulse2.com | ||
| 28.07. | MaaT Pharma Secures €37.5 Million Loan From European Investment Bank (EIB) Marking a New Step in Advancing its Clinical Program in Hemato-Oncology | 436 | Business Wire | Tranche-based financing to support clinical development for the Company's late-stage assets in hemato-oncology including Xervyteg currently under review for potential approval by the EMA and MaaT033... ► Artikel lesen | |
| 24.07. | MaaT Pharma: Half-year Report to the Liquidity Contract With Kepler Cheuvreux | 255 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 07.07. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 267 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 02.07. | MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg in acute Graft-versus Host Disease in Europe | 462 | Business Wire | MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg(MaaT013), its first in class treatment proposed for patients... ► Artikel lesen | |
| 24.06. | MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting | 311 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies(MET) dedicated to enhancing... ► Artikel lesen | |
| MAAT PHARMA Aktie jetzt für 0€ handeln | |||||
| 19.06. | MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 | 409 | Business Wire | Marketing Authorization application of Xervyteg (MaaT013) in acute graft-versus-host-disease submitted to the European Medicines Agency (EMA) in June 2025
MAA could be expected in H2 2026... ► Artikel lesen | |
| 13.06. | MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease | 372 | Business Wire | Oral presentation highlights updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with Xervyteg
Independent dataset from EAP reinforces... ► Artikel lesen | |
| 02.06. | MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg (MaaT013) in Acute Graft-versus-Host Disease | 424 | Business Wire | MaaT Pharma submitted today a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its product candidate MaaT013, under the registered brand name of Xervyteg
Xervyteghas... ► Artikel lesen | |
| 14.05. | MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress | 329 | Business Wire | Oral presentation will highlight updated data in Early Access Program (EAP) for 173 patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013.
Poster presentation selected... ► Artikel lesen | |
| 14.05. | MaaT Pharma to Hold Annual General Meeting on June 20, 2025 | 374 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 13.05. | MaaT Pharma Provides Business Update and Reports Financial Results for the First Quarter 2025 | 349 | Business Wire | Positive results from Phase 3 trial for MaaT013 in acute Graft-versus-Host disease (aGvHD); topline results showed a 62% gastrointestinal overall response rate at Day 28 and 1-year expected Overall... ► Artikel lesen | |
| 12.05. | MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) | 355 | Business Wire | Regulatory News:
MaaT Pharma(EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 29.04. | AACR 2025: MaaT Pharma, the gut microbiome, and immuno-oncology | - | pharmaphorum | ||
| 28.04. | MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 | 334 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 14.04. | Availability of MaaT Pharma's 2024 Universal Registration Document (URD) | 286 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 08.04. | MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT | 351 | Business Wire | Following a milestone unblinded interim safety review, the independent Data Safety Monitoring Board (DSMB) has recommended that the study proceed without modification. MaaT033, a pooled... ► Artikel lesen | |
| 07.04. | MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co | 465 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen | |
| 04.04. | MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 391 | Business Wire | Article 223-16 of the General Regulations of the Financial Markets Authority
(AMF Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage... ► Artikel lesen | |
| 31.03. | MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients' Responses to Immunotherapies | 454 | Business Wire | Regulatory News:
MaaT Pharma (EURONEXT: MAAT the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEIDELBERG PHARMA | 3,470 | -1,70 % | Heidelberg Pharma nach Telix-Rückschlag: "Eine sehr enttäuschende Nachricht" | Bittere Pille für die australische Telix Pharmaceuticals. Ende August hat die US-Zulassungsbehörde FDA kein grünes Licht für Zircaix erteilt. Das negative Votum belastet auch Heidelberg Pharma, da die... ► Artikel lesen | |
| BAVARIAN NORDIC | 31,340 | -0,41 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 05.09.2025 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,690 | +0,07 % | Down 34%, Should You Buy the Dip on Viking Therapeutics? | ||
| INTELLIA THERAPEUTICS | 10,260 | +1,94 % | Cathie Wood's ARK ETF adjusts portfolio, sells Roku stock, buys CRISPR and Intellia | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,085 | +1,65 % | PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq | ||
| CENTOGENE | 0,120 | +9,09 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 3,902 | +1,43 % | Deals im Milliarden-Markt für Psychedelika: AbbVie, Atai Life Sciences, Neural Therapeutics | ||
| BIOMERIEUX | 114,70 | +0,70 % | BIOMERIEUX: bioMérieux - First-Half 2025 Results | ||
| AC IMMUNE | 1,864 | +0,11 % | AC Immune SA: AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway | AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce... ► Artikel lesen | |
| CYCLACEL | 6,129 | -4,53 % | Cyclacel Pharmaceuticals, Inc. - 8-K, Current Report | ||
| CYBIN | 5,450 | +1,87 % | Cybin Inc (2): Cybin completes enrolment in phase 2 study on CYB004 | ||
| ADICET BIO | 0,606 | -6,98 % | MaxCyte, Inc: MaxCyte Signs Platform License Agreement with Adicet Bio | MaxCyte's Flow Electroporation® technology and ExPERT platform to support development of Adicet's gamma delta T cell therapy gene edited programs ROCKVILLE, Md., Aug. 04, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| GENUS | 29,600 | 0,00 % | Genus - Additional Listing | ||
| ANAPTYSBIO | 18,500 | -2,12 % | AnaptysBio, Inc.: Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update | Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trialEnrollment completed for rosnilimab Phase 2 ulcerative colitis trial;... ► Artikel lesen |
Das Unternehmen MAAT PHARMA SA kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,220 (+5,93 %) liegt der Kurs bei 3,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAAT PHARMA SA finden Sie auf Wallstreet Online.